Aprea Therapeutics, Inc.
APRE
$0.79
$0.000.01%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -98.40% | -99.49% | -78.97% | -57.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -98.40% | -99.49% | -78.97% | -57.30% |
| Cost of Revenue | -35.11% | -57.24% | -42.42% | -25.24% | 55.15% |
| Gross Profit | 30.57% | 53.30% | 34.30% | 10.12% | -90.24% |
| SG&A Expenses | 3.07% | 52.65% | -7.78% | -13.89% | -8.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.25% | -22.89% | -29.93% | -20.47% | 20.33% |
| Operating Income | 16.04% | 18.07% | 23.91% | 11.93% | -29.71% |
| Income Before Tax | 16.40% | 15.17% | 21.44% | 6.66% | -39.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.40% | 15.17% | 21.44% | 6.66% | -39.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.40% | 15.17% | 21.44% | 6.66% | -39.95% |
| EBIT | 16.04% | 18.07% | 23.91% | 11.93% | -29.71% |
| EBITDA | 16.06% | 18.10% | 23.94% | 11.96% | -29.80% |
| EPS Basic | 65.87% | 34.29% | 26.78% | 8.91% | 1.97% |
| Normalized Basic EPS | 65.89% | 34.30% | 26.78% | 8.90% | 1.96% |
| EPS Diluted | 66.08% | 34.29% | 26.78% | 8.91% | 1.39% |
| Normalized Diluted EPS | 65.89% | 34.30% | 26.78% | 8.90% | 1.96% |
| Average Basic Shares Outstanding | 145.01% | 29.11% | 7.29% | 2.46% | 42.77% |
| Average Diluted Shares Outstanding | 145.01% | 29.11% | 7.29% | 2.46% | 42.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |